Imagen por defecto

admin

‘If you don’t exercise, you break’: Physical activity key in osteoporosis intervention

ORLANDO — Exercise can supplement the efficacy of several therapies used to treat osteoporosis, according to a presenter at the 2022 Rheumatology Nurses Society Annual Conference.
“You get old, and if you don’t exercise, you break,” Jacqueline M. Fritz, RN, MSN, RN-BC, an infusion specialist at the Arthritis and Osteoporosis Center, in La Palma, California, told attendees.
Regarding treatment, Fritz highlighted denosumab, which blocks RANK ligand and is given subcutaneously every 6 months. Meanwhile, the antisclerostin romosozumab (Evenity, Amgen) is effective but should

FDA approves darolutamide for metastatic prostate cancer subset

The FDA approved darolutamide tablets in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer.
Darolutamide (Nubeqa, Bayer) is an androgen receptor (AR) inhibitor designed to inhibit androgen binding, AR nuclear translocation and AR-mediated transcription.
The FDA based the approval on results of the randomized phase 3 ARASENS trial, which included 1,306 men with newly diagnosed metastatic hormone-sensitive prostate cancer.
Researchers assigned men to androgen deprivation therapy and docetaxel plus either 600 mg darolutamide twice daily or placebo.
OS served as the

$31 million study to test use of inhaled corticosteroids, azithromycin in asthma treatment

With $31 million in funding from the Patient-Centered Outcomes Research Institute, researchers will investigate the effectiveness of inhaled corticosteroids and azithromycin, used either alone or together, in treating asthma.
The American Academy of Family Physicians (AAFP) and Penn State College of Medicine will collaborate on the Individualizing Treatment for Asthma in Primary Care (iTREAT-PC) study, which will test these interventions.
For 16 months, the researchers will follow more than 3,000 patients aged 12 to 75 years with persistent asthma requiring inhaled steroids for management at 10

FDA approves Enhertu for HER2-low breast cancer

The FDA approved fam-trastuzumab deruxtecan-nxki for treatment of certain patients with unresectable or metastatic HER2-low breast cancer.
The approval — the first for a targeted therapy to treat HER2-low breast cancer — applies to patients who received prior chemotherapy in the metastatic setting, or those whose disease progressed during or within 6 months of adjuvant chemotherapy.
Fam-trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) is a novel antibody-drug conjugate with three components: a humanized anti-HER2 immunoglobulin G1 monoclonal antibody with the same amino

COVID-19, burnout may lead to nursing workforce shortage ‘in years to come’

ORLANDO — Burnout and the personal impacts of the COVID-19 pandemic among health care providers may lead to a long-term nursing shortage nationwide, according to a presenter at the 2022 Rheumatology Nurses Society Annual Conference.
“The combination of burnout and the pandemic could put the United States in a position of a nursing workforce shortage in years to come,” Carrie Beach, BSN, RN-BC, president of RNS and staff rheumatology nurse at the Columbus Arthritis Center, in Columbus, Ohio, told attendees.

To combat these effects, Beach stressed that self-care and positive

Polioviruses detected in sewage in two NY counties, indicating local spread

Poliovirus has been detected in wastewater in two neighboring New York counties, indicating local transmission, health officials said.
The virus was detected in wastewater samples from Rockland and Orange counties, which have polio vaccination rates roughly 20 percentage points below the state average. The counties are north of New York City.
Health officials last month announced a case of vaccine-derived polio in an unvaccinated Rockland County resident who was left paralyzed. It was the first case of polio recorded in the United States since 2013.
According to the New York State Department of

Dosing of AR-15512 for dry eye begins in next step of COMET program

The first subject has been dosed in the phase 3 registrational COMET-3 study investigating AR-15512 for the treatment of dry eye disease, according to a press release from Aerie Pharmaceuticals.
The randomized, double-masked, vehicle-controlled multicenter clinical study will enroll approximately 460 participants with dry eye disease who will be randomly assigned to receive either AR-15512 0.003% or AR-15512 vehicle as a drop twice daily in each eye for 3 months. Tear production, measured by unanesthetized Schirmer’s test, is the primary efficacy assessment, with a secondary measure of

Q&A: Dialysis providers charge Medicare Advantage plans more than Medicare

Due to a highly consolidated market, large dialysis providers charge Medicare Advantage plans 27% more for dialysis services than what is charged for Medicare.
Further, the markups, also imposed by other providers, could impact the out-of-pocket spending of patients on dialysis.
Researchers from the University of Southern California (USC) examined 1.06 million claims in 2016 and 2017 for which Medicare Advantage was the primary payer to compare Medicare Advantage outpatient dialysis spending to what fee-for-service Medicare would have paid under the ESRD Prospective Payment System.
For each

FDA rejects expanded use of Nuplazid for Alzheimer’s-related psychosis

The FDA has declined to approve a supplemental new drug application for the expanded use of Nuplazid to treat psychosis related to Alzheimer's disease.
According to a release from Acadia Pharmaceuticals, the FDA concluded there were limitations in the interpretability of Acadia’s antipsychotic drug study for Nuplazid (pimavanserin, Acadia) and an additional study would be required.
The decision is another blow to Acadia, after the Psychopharmacologic Drugs Advisory Committee voted nine to three on June 20 that available data did not support the conclusion that pimavanserin was effective

Speaker: Recognizing patients’ emotional stress can reduce CV risk, improve outcomes

LOUISVILLE, Ky. — A speaker at the American Society for Preventive Cardiology Congress on CVD Prevention called on clinicians to have greater consideration for the effects of psychosocial factors on CVD and related outcomes.
During a presentation, Kavitha Chinnaiyan, MD, FACC, FSCCT, professor of medicine at Oakland University William Beaumont School of Medicine and Beaumont Hospital in Royal Oak, Michigan, detailed the potential psychosocial and emotional triggers of incident CVD and emphasized the importance of cultivating resilience and neuroplasticity in at-risk patients.
“Mental